Nogapendekin Alfa Inbakicept

other

Identifier: CI-DRUG-00000814
Entity page: /drug/nogapendekin-alfa-inbakicept ↗
Edges: 22

Neighbours: 12 cancers3 genes6 trials
Drawn: 21 of 21 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Nogapendekin Alfa Inbakicept approved for …APPROVED_FOR2 of 2
→ approved for	Non-Muscle Invasive Bladder Carcinomasubtype	supports	FDA ORIG	Non-Muscle Invasive Bladder Carcinoma	1	Regulatory	openfda	graph →
→ approved for	Non-Muscle Invasive Bladder Carcinomasubtype

Nogapendekin Alfa Inbakicept targets …TARGETS3 of 3
→ targets	IL2RB	—	AGONIST	—	1	Curated	chembl	graph →
→ targets	IL15RA	—	AGONIST	—	1	Curated	chembl	graph →
→ targets	IL2RG	—	AGONIST	—	1	Curated	chembl	graph →

Nogapendekin Alfa Inbakicept targets …TARGETS3 of 3

→ targets

IL2RB

—

AGONIST

—

Curated

Nogapendekin Alfa Inbakicept investigated in trials for …INVESTIGATED_IN_TRIALSderived11 of 11
→ investigated in trials for	Lung Non-Small Cell Carcinoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Bladder Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Head and Neck Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Head and Neck Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Myxoid Liposarcoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myxoid Liposarcoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Oropharyngeal Squamous Cell Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Oropharyngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Pancreatic Neoplasm 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Round Cell Liposarcoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Round Cell Liposarcoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Synovial Sarcoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Synovial Sarcoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Urothelial Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →

Nogapendekin Alfa Inbakicept studied in …STUDIED_INderived6 of 6
→ studied in	NCT07217496Phase 1 · not yet recruiting N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer · 6 trials list this drug (4 active)	—	—	Urothelial Carcinoma,Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07488884Phase 1 · withdrawn Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer · 6 trials list this drug (4 active)	—	—	Malignant Pancreatic Neoplasm,Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07261657early Phase 1 · recruiting N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy · 6 trials list this drug (4 active)	—	—	Round Cell Liposarcoma,Myxoid Liposarcoma,Synovial Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07355205Phase 1/Phase 2 · recruiting First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer · 6 trials list this drug (4 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07524257Phase 3 · withdrawn Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC · 6 trials list this drug (4 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07628062Phase 2 · not yet recruiting Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation · 6 trials list this drug (4 active)	—	—	Malignant Head and Neck Neoplasm,Oropharyngeal Squamous Cell Carcinoma,Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths